GCIA
CYT

Gabelli & Co Investment Advisers’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,026,000
Closed -$3.12M – 286
2023
Q4 		$3.12M Buy
1,026,000
+609,800
+147% +$1.85M 0.59% 39
2023
Q3 		$1.18M Buy
+416,200
New +$1.15M 0.19% 75

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.65B AUM 18.1% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Gabelli & Co Investment Advisers's CYT Position: Q1 2024 in Review

Gabelli & Co Investment Advisers sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 1,026,000 shares — an estimated $3.12M sold.

Gabelli & Co Investment Advisers first reported a position in CYT in Q3 2023 and held it in 2 quarters. The position peaked at $3.12M in Q4 2023. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Gabelli & Co Investment Advisers reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 1,026,000 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.12M.
  • Gabelli & Co Investment Advisers first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • Gabelli & Co Investment Advisers's Cyteir Therapeutics, Inc. Common Stock position peaked at $3.12M in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2024, filed 14 May 2024.